CTMX News and Press, CytomX Therapeutics Inc. From 09/10/25

2025-09-10 16:26:32 ET CytomX Therapeutics, Inc. (CTMX) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT... Read the full article on Seeking Alpha For further details see: CytomX Therapeutics, Inc. (CTMX) Presents At Morgan Stanley 23rd ...

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. Cantor Global Hea...

2025-08-13 12:15:10 ET Oppenheimer analyst issues OUTPERFORM recommendation for CTMX on August 13, 2025 02:03PM ET. The previous analyst recommendation was Outperform. CTMX was trading at $1.845 at issue of the analyst recommendation. The overall analyst consensus : BUY....

- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company’s goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all expansion doses - S...

2025-08-08 18:10:33 ET CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Conference Call August 07, 2025, 05:00 PM ET Company Participants Christopher W. Ogden - SVP & Chief Financial Officer Sean A. McCarthy - Chairman & CEO Conference Call Participant...

2025-08-08 17:05:35 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: CytomX Therapeutics: Updated Outlook For Late 2025

2025-08-07 16:18:23 ET More on CytomX CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish? CytomX upgraded at H.C. Wainwright on trial data for cancer drug Read the full article on Seeking Alpha For further details see: CytomX GAAP EP...

- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track for data update in Q1 2026. Phase 2 study initiation in CRC antic...

Leatt Corp (LEAT) is expected to report for Q2 2025 MDU Resources Group Inc. (Holding Company) (MDU) is expected to report $0.13 for Q2 2025 Video Display Corp. (VIDE) is expected to report for quarter end 2025-05-31 Alarm.com Holdings Inc. (ALRM) is expected to report $0.38 for Q2 20...

CytomX Therapeutics Inc. (CTMX) is expected to report $-0.06 for Q2 2025